Nearly a third of abnormalities found after first-trimester screening are different than expected:10-year experience from a single center

Prenatal Diagnosis

Volumn 33, Issue 3, 2013, Pages 251-256

  Alamillo, Christina M L ^a   Krantz, David ^b   Evans, Mark ^c   Fiddler, Morris ^a   Pergament, Eugene ^a  

^a Northwestern Reproductive Genetics Inc   (United States)

^b PERKINELMER INC   (United States)

^c Comprehensive Genetics Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ANEUPLOIDY; ARTICLE; BLOOD SAMPLING; DOWN SYNDROME; FALSE NEGATIVE RESULT; FIRST TRIMESTER PREGNANCY; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MATERNAL AGE; MATERNAL BLOOD; MISSED ABORTION; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE; PRENATAL SCREENING; PRIORITY JOURNAL; TRISOMY 13; TRISOMY 18;

ABNORMAL KARYOTYPE; ADOLESCENT; ADULT; AMNIOCENTESIS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CHORIONIC VILLI SAMPLING; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; HUMANS; KARYOTYPING; MATERNAL AGE; MIDDLE AGED; MOSAICISM; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; TRISOMY; YOUNG ADULT;

EID: 84874531862     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.4054     Document Type: Article

References (21)

1. Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and Free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol 2004;191(4):1446-51.
2. Wapner R, Thom E, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First trimester screening for trisomies 21 and 18. N Engl J Med 2003;349(15):1405-13.
3. Spencer K, Souter V, Tul N, et al. A screening program for trisomy 21 at 10-14weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999;13(4):231-7.
4. Kagan KO, Wright D, Maiz N, et al. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;32(4):488-92.
5. Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenat Diagn 2002;22(10):877-9.
6. Kagan KO, Wright D, Baker A, et al. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31(6):618-24.
7. Krantz DA, Hallahan TW, Orlandi F, et al. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000;96(2):207-13.
8. Perni SC, Predanic M, Kalish RB, et al. Clinical use of first-trimester aneuploidy screening in a United States population can replicate data from clinical trials. Am J Obstet Gynecol 2006;194(1):127-30.
9. Palomaki GE, Lee JE, Canick JA, et al. Technical standards and guidelines: prenatal screening for Down syndrome that includes first-trimester biochemistry and/or ultrasound measurements. Genet Med 2009;11:669-81.
10. Krantz D, Hallahan T, Ravens R, et al. First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay. Prenat Diagn 2000;31(9):869-74.
11. American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007;109(1):217-27.
12. American College of Obstetrics and Gynecology. ACOG Practice Bulletin No. 88: invasive prenatal testing for aneuploidy. Obstet Gynecol 2007;110(6):1459-67.
13. +6weeks Scan. London: Fetal Medicine Foundation, London, 2004.
14. Donaldson MDC, Gault EJ, Tan KW, Dunger DB. Optimising management in Turner syndrome: from infancy to adult transfer. Arch Dis Child 2006;91(6):513-20.
15. Urbach A, Benvenisty N. Studying early lethality of 45, XO (Turner's syndrome) embryos using human embryonic stem cells. PLoS One 2009;4(1):e4175.
16. Menasha J, Levy B, Hirschorn K, Kardon NB. Incidence and spectrum of chromosome abnormalities in spontaneous abortions: new insights from a 12year study. Genet Med 2005;7(4):251-63.
17. Spencer K, Tul N, Nicolaides KH. Maternal serum free β hCG and PAPP-A in fetal sex chromosome defects in the first trimester. Prenat Diagn 2000;20:390-94.
18. Kagan KO, Avgidou K, Molina FS, et al. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstet Gynecol 2006;107:6-10.
19. Gardner RJ, Sutherland GR. Chromosome Abnormalities and Genetic Counseling. (3rd ed). New York, NY: Oxford University Press. 2004.
20. Gardner RJ. Sutherland GR Chromosome Abnormalities and Genetic Counseling. (1st ed). New York, NY: Oxford University Press. 1996.
21. Benn P, Borrell A, Cuckle H, et al. Prenatal Detection of Down Syndrome using Massively Parallel Sequencing (MPS): a rapid response statement from a committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2012;32(1):1-2.